Scott Cramer, University of Colorado Denver (IMAGE)

University of Colorado Anschutz

Scott Cramer, University of Colorado Denver

Caption

Scott Cramer, Ph.D., and University of Colorado Cancer Center colleagues show that of prostate cancer with combination MAP3K7 and CHD1 deletions, about 50 percent will have recurrent disease.

Credit

CU Cancer Center

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.